Infusion of Allogeneic Mesenchymal Stromal Cells After Liver Transplantation: A 5‐Year Follow‐Up

Various properties of mesenchymal stromal cells (MSCs) might be particularly of interest after liver transplantation (LT). In this article, we report the long‐term results of a prospective, controlled, and first‐in‐human phase 1 study evaluating the safety of a single MSC infusion after LT. A total...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Liver transplantation 2022-04, Vol.28 (4), p.636-646
Hauptverfasser: Vandermeulen, Morgan, Mohamed‐Wais, Maleyko, Erpicum, Pauline, Delbouille, Marie‐Hélène, Lechanteur, Chantal, Briquet, Alexandra, Maggipinto, Gianni, Jouret, François, Beguin, Yves, Detry, Olivier
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Various properties of mesenchymal stromal cells (MSCs) might be particularly of interest after liver transplantation (LT). In this article, we report the long‐term results of a prospective, controlled, and first‐in‐human phase 1 study evaluating the safety of a single MSC infusion after LT. A total of 10 LT recipients treated with standard immunosuppression received 1.5 to 3 × 106/kg third‐party unrelated MSCs on postoperative day 3 and were prospectively compared with a control group of 10 LT recipients. Primary endpoints were set to prospectively detect potentially delayed adverse effects of MSC infusion, particularly the occurrence of infections and cancers. Secondary endpoints of liver graft and patient survival, graft rejection and function, occurrence of bile duct complications, and development of donor‐specific anti–human leukocyte antigen (HLA) antibodies (DSA) against liver or MSC donors were studied. The median follow‐up was 85 months. There was no difference in overall rates of infection or cancer at 5 years of follow‐up between the 2 groups. There was also no difference in secondary endpoints. The prevalence of de novo liver DSAs related to HLA mismatches was twice as high in the MSC group compared with the control group. All of the de novo class II HLA antibodies against MSCs were linked to a shared HLA mismatch between the liver and MSCs. This study confirms the safety of a single MSC infusion after LT. The potential benefits of MSC injections in the context of organ transplantation have yet to be demonstrated by larger prospective studies. The development of anti‐HLA antibodies against an MSC donor should be further evaluated, especially in cases of shared HLA mismatches between graft and MSC donors, despite the fact that no deleterious effect has been detected.
ISSN:1527-6465
1527-6473
DOI:10.1002/lt.26323